What is OnCusp?
OnCusp Therapeutics is a global biopharmaceutical company dedicated to advancing a focused portfolio of first-in-class oncology assets. The company's strategy centers on transforming promising research into validated medicines. Led by a founding team with extensive experience in business development, clinical development, and the establishment of startup biopharmaceutical entities, OnCusp is positioned to navigate the complex path from discovery to patient impact. The company's focus on oncology assets suggests a strategic commitment to addressing critical unmet needs within cancer treatment.
How much funding has OnCusp raised?
OnCusp has raised a total of $125M across 2 funding rounds:
Angel/Seed
$25M
Series A
$100M
Angel/Seed (2021): $25M with participation from Oriza Seed Fund, AIHC Capital, BioTrack Capital, and Sequoia Capital
Series A (2024): $100M led by Catalio Capital Management, F-Prime Capital, Novo Holdings, Marshall Wace, BioTrack Capital, and OrbiMed
Key Investors in OnCusp
Catalio Capital Management
Catalio Capital Management is a New York-based investment firm specializing in innovative healthcare investing across private, public, and credit markets, focusing on breakthrough biomedical technology companies.
F-Prime Capital
F-Prime Capital is a Massachusetts-based investment firm established in 2002, dedicated to investing in health care and technology for other companies.
Novo Holdings
Novo Holdings is a Danish private limited liability company, established in 1999 and headquartered in Hellerup, Denmark, wholly owned by the Novo Nordisk Foundation.
What's next for OnCusp?
The recent major strategic investment indicates a strong vote of confidence in OnCusp Therapeutics' scientific approach and leadership. This capital infusion, part of its $125M in total financing, will likely fuel the progression of its oncology pipeline through critical clinical development milestones. The company's trajectory suggests a focus on scaling operations, potentially expanding its research and development capabilities, and preparing for future commercialization efforts. Strategic partnerships and further financing rounds may be anticipated as OnCusp advances its assets through late-stage development.
See full OnCusp company page
